(NASDAQ: FGEN) Fibrogen's forecast annual revenue growth rate of 51.23% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Fibrogen's revenue in 2025 is $29,621,000.On average, 2 Wall Street analysts forecast FGEN's revenue for 2025 to be $605,501,736, with the lowest FGEN revenue forecast at $605,501,736, and the highest FGEN revenue forecast at $605,501,736. On average, 2 Wall Street analysts forecast FGEN's revenue for 2026 to be $706,418,692, with the lowest FGEN revenue forecast at $605,501,736, and the highest FGEN revenue forecast at $807,335,648.
In 2027, FGEN is forecast to generate $12,246,272,611 in revenue, with the lowest revenue forecast at $605,501,736 and the highest revenue forecast at $23,887,043,485.